The administration of NIMO prior to the administration of CIS therapy has been demonstrated to result in the enhanced activation of AKT and CREB in neuronal and glial cells7,8, which in turn has been shown to reduce the rate of cell death. Here, AKT1 is linked to in situ carcinoma.